Vera Therapeutics, Inc.

NASDAQ: VERA · Healthcare · Biotechnology

PublicHQ Brisbane, CA · San MateoCIK 0001831828Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 56DQ —GM —SS 61

v0.1 · 35/100 weight · pillars only

↑ Altman-Z, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$299.6M

Employees

249

as of 2026-08-08

Market cap

$2.4B

as of 2026-08-08

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$299.6M-$299.6M2025

Operating income-$315.5M-$315.5M2025

Total assets$734.7M$734.7M2025

Liabilities$130.2M$130.2M2025

Equity$604.5M$604.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Vera Therapeutics, Inc.’s financial profile?

Vera Therapeutics, Inc. earned -$299.6M in FY2025 net income.

Peers · Healthcare

Kodiak Sciences Inc.——Trevi Therapeutics, Inc.——Mineralys Therapeutics, Inc.——Sionna Therapeutics, Inc.——Biohaven Ltd.——Kailera Therapeutics, Inc.——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Equinix, Inc.$9.2B74B Robinhood Markets, Inc.$4.5B67B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOMarshall Fordyce

SectorHealthcare

IndustryBiotechnology

HeadquartersBrisbane, CA

ExchangeNASDAQ: VERA

Employees249

IPO date2021-05-14

Latest filings

10-Q2026-08-10 8-K2026-08-10 8-K2026-07-09 8-K2026-07-07 8-K2026-06-02 8-K2026-05-26 8-K2026-05-07 10-Q2026-05-07

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.